title: A multifunctional alanine-rich anti-inflammatory peptide BCP61 showed potent inhibitory effects by inhibiting both NF-κB and MAPK expression.
abstract: The purified BCP61 was reported to be a unique low-molecular-weight (MW) anti-microbial peptide because of its non-identical alanine-rich N-terminal sequence. In this study, we investigated the anti-inflammatory effects of BCP61 on induction of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), pro-inflammatory cytokines, nuclear factor-kappa B (NF-κB), and mitogen-activated protein kinases (MAPKs) in lipopolysaccharide (LPS)-stimulated Raw 264.7 cells. The treatment with BCP61, with varying concentrations of 10, 50, and 100 μg/mL, inhibited levels of expression of LPS-induced NF-κB and MAPKs (extracellular signal-related kinases (ERKs), c-Jun NH2-terminal kinase (JNK), and mitogen-activated protein (p38)) as well as production of pro-inflammatory mediators, such as nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). The results suggested that BCP61 prevents inhibitor of kappa B (IκBα) phosphorylation and degradation, thereby inhibiting the nuclear translocation of the p65 protein. We do report that the use of BCP61 in the treatment of inflammation as well as microbial infection could be a potent therapeutic candidate.
authors.affiliation: Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, Korea.
authors.forename: Yun Hee
authors.initials: YH
authors.lastname: Choi
authors.affiliation: Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, Korea.
authors.forename: Yoon Seok
authors.initials: YS
authors.lastname: Choi
authors.affiliation: Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, Korea.
authors.forename: Young Kyun
authors.initials: YK
authors.lastname: Kim
authors.affiliation: Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, Korea.
authors.forename: Md Saifur
authors.initials: MS
authors.lastname: Rahman
authors.affiliation: Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, Korea.
authors.forename: G C
authors.initials: GC
authors.lastname: Pradeep
authors.affiliation: Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 501-759, Korea. jcyu@chosun.ac.kr.
authors.forename: Jin Cheol
authors.initials: JC
authors.lastname: Yoo
authors.affiliation: Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Myongji-ro 116, Cheoin-gu, Yongin, Gyeonggi-Do, 449-728, Korea. jwsuh@mju.ac.kr.
authors.forename: Joo-Won
authors.initials: JW
authors.lastname: Suh
mesh_terms: D000409:Alanine; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D020672:I-kappa B Proteins / Q000378:metabolism; D007249:Inflammation / Q000188:drug therapy; D018836:Inflammation Mediators / Q000378:metabolism; D008070:Lipopolysaccharides; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D051379:Mice; D010455:Peptides; D010766:Phosphorylation / Q000187:drug effects; D000067996:RAW 264.7 Cells; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; C000617975:BCP61 peptide, Bacillus; D001426:Bacterial Proteins; D016207:Cytokines; D020672:I-kappa B Proteins; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D010455:Peptides; D051996:Transcription Factor RelA; D000409:Alanine
keywords: MAPKs; NF-κB; RAW 264.7; anti-inflammatory peptide bcp61